Sagimet Biosciences SGMT Ratios (2023-2026)

NASDAQ SGMT
$10.94 +0.02 (+0.18%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Sagimet Biosciences Quarterly Ratios

Periods 12 quarters
Latest Jun 2026

Sagimet Biosciences ratios data for the quarter ended Jun 2026. These financial ratios cover 12 quarters of results from Sep 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Profitability
EBT Margin -317.85%
EBIT Margin -372.60%
EBITDA Margin -372.60%
Operating Margin -372.60%
Net Margin -317.85%
FCF Margin -193.95%
Efficiency
Assets AverageAssets Avg. 62.21M99.82M145.62M191.77M181.90M167.52M153.22M141.79M132.90M122.44M112.12M185.59M
Valuation
Price to EarningsP/E -31.69-15.22-17.90-10.28-6.09-8.71-5.25-23.62-17.25-20.01-14.39-29.43
Price to SalesP/S 100.74
Price to BookP/B 2.061.360.830.600.520.910.761.881.871.721.661.60
Enterprise Value 99.64M29.20M-36.31M-57.23M-63.45M-10.17M-39.61M119.92M106.02M78.36M65.59M170.45M
EV to EBIT -13.37-3.084.145.403.750.561.99-10.06-7.40-7.28-5.60-10.78
EV to EBITDA -13.37-3.084.145.403.750.561.99-10.06-7.40-7.28-5.60-10.78
Market Capitalization 201.48M124.10M157.39M109.15M89.04M141.08M104.96M245.33M222.71M191.49M170.12M410.58M
Price to FCFP/FCF -51.94-17.52-25.35-19.37-4.55-12.80-7.22-26.96-21.88-16.18-19.76-36.99
EV to FCF -25.69-4.125.8510.163.240.922.73-13.18-10.41-6.62-7.62-15.36
EV to CFO -25.69-4.125.8510.163.240.922.73-13.18-10.41-6.62-7.62-15.36
Return Ratios
Return on Sales [ROS]ROS -372.60%
Return on Capital Employed [ROCE]ROCE -50.14%-32.64%-33.39%-49.71%-51.97%-48.48%-45.62%-29.21%
Return on Assets [ROA]ROA -43.87%-28.30%-20.84%-17.69%-23.19%-29.99%-40.08%-43.15%-44.75%-43.15%-39.86%-26.00%